Market Cap 31.95M
Revenue (ttm) 640,000.00
Net Income (ttm) -69.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,921.88%
Debt to Equity Ratio -1.15
Volume 1,023,200
Avg Vol 1,581,184
Day's Range N/A - N/A
Shares Out 27.08M
Stochastic %K 22%
Beta 0.30
Analysts Strong Sell
Price Target $14.80

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 475 238 6837
Address:
555 Long Wharf Drive, 12th Floor, New Haven, United States
BayAreaBiotech
BayAreaBiotech Apr. 5 at 7:15 AM
$BTAI I have achieved my target of 100k shares since my post about a month ago. I have locked my shares for the PDUFA! Let’s see if the science and patient need prevail with a good partnership or the incompetent management continues to push this down.
0 · Reply
Duskfall
Duskfall Apr. 4 at 6:15 PM
Happy Easter everyone! I hope you took advantage of the dip. Starting next week, this will be working 💯 $VXRT $BTAI $AEMD $TOVX $CGTX
0 · Reply
SrTxan
SrTxan Apr. 4 at 7:14 AM
$BTAI Three posts since Nasdaq closed on Thursday and all of them apocalyptic. I love how people spend their time during holidays thinking about us. Looks like Ernesto is sending his clowns to war. We’ll see very soon why.
1 · Reply
AllAboutTheBread
AllAboutTheBread Apr. 4 at 1:00 AM
$BTAI this things lost 90% of its value in 3 months.
1 · Reply
Mptxop
Mptxop Apr. 3 at 12:47 PM
$BTAI keep holding! Dilution and RS’s won’t be an issue!
2 · Reply
Paxhawig
Paxhawig Apr. 3 at 11:15 AM
$BTAI deadth
0 · Reply
Nickandrun
Nickandrun Apr. 2 at 3:43 PM
$BTAI I see this restabilizing somewhere around the 1.50-2.00 mark for a while, I think this area is pretty much the burns from earnings and people who decided to take major losses for no reason, underwhelming news, and repricing from firms.
1 · Reply
CADBUCK
CADBUCK Apr. 2 at 2:58 PM
$BTAI should we hold until next November or is it a dead stock ready to dilute /offfering soon?
1 · Reply
SrTxan
SrTxan Apr. 2 at 2:51 PM
$BTAI We’ve already seen the relationship between Rodman & Renshaw and HCW, the same players within the same ecosystem, where Rodman acted as the placement agent for the latest BTAI offering and holds warrants at $2.01 A few days ago they were putting out a $17 price target. HCW has had a close relationship with Rodman for over 10 years (same game, same interests) HCW hasn’t issued a real BUY on BTAI in years, yet keeps putting out high, unrealistic price targets. Anyone who says there is no conflict of interest between these firms is blatantly lying. The SEC should step in and stop allowing analysts tied to deal makers to publish completely unrealistic price targets. And it doesn’t stop there: HCW and Rodman have overlapping interests with hedge funds that are or have been involved in BTAI, many of them holding warrants at different levels. They’re trying to push us out… But at least I’m not going anywhere I’ll be here exposing all of it, and there’s a lot to expose.
2 · Reply
fatpie68
fatpie68 Apr. 2 at 2:33 PM
"Recent Street research reflects a split view on $BTAI , with some analysts emphasizing upside tied to the at-home agitation portfolio and others focusing more on the impact of equity dilution on upside potential. Some bullish analysts point to what they describe as an extreme disconnect between enterprise value and the company’s risk adjusted cash flow potential. They suggest that if core programs progress as planned, there could be room for valuation to move closer to those estimates." https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-btai/bioxcel-therapeutics/o5r3dewc-btai-upcoming-regulatory-milestones-will-drive-momentum-following-key-phase-3-success/updates/14-14-analysts-now-set-an-updated-dollar1425-price-target-for-bioxcel?utm_source=Braze&utm_medium=email&utm_campaign=CommunityDigest
0 · Reply
Latest News on BTAI
Why Are BioXcel Therapeutics Shares Down Friday?

Mar 6, 2026, 10:27 AM EST - 4 weeks ago

Why Are BioXcel Therapeutics Shares Down Friday?


BioXcel Therapeutics Stock Rallies Opioid Study Success

Mar 5, 2026, 8:53 AM EST - 4 weeks ago

BioXcel Therapeutics Stock Rallies Opioid Study Success


BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

Aug 27, 2025, 12:01 PM EDT - 7 months ago

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment


BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:29 AM EDT - 7 months ago

BioXcel's agitation drug meets main goal in at-home study


BioXcel Therapeutics Announces Reverse Stock Split

Feb 6, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Reverse Stock Split


BioXcel Therapeutics Announces Proposed Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering


BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference


BayAreaBiotech
BayAreaBiotech Apr. 5 at 7:15 AM
$BTAI I have achieved my target of 100k shares since my post about a month ago. I have locked my shares for the PDUFA! Let’s see if the science and patient need prevail with a good partnership or the incompetent management continues to push this down.
0 · Reply
Duskfall
Duskfall Apr. 4 at 6:15 PM
Happy Easter everyone! I hope you took advantage of the dip. Starting next week, this will be working 💯 $VXRT $BTAI $AEMD $TOVX $CGTX
0 · Reply
SrTxan
SrTxan Apr. 4 at 7:14 AM
$BTAI Three posts since Nasdaq closed on Thursday and all of them apocalyptic. I love how people spend their time during holidays thinking about us. Looks like Ernesto is sending his clowns to war. We’ll see very soon why.
1 · Reply
AllAboutTheBread
AllAboutTheBread Apr. 4 at 1:00 AM
$BTAI this things lost 90% of its value in 3 months.
1 · Reply
Mptxop
Mptxop Apr. 3 at 12:47 PM
$BTAI keep holding! Dilution and RS’s won’t be an issue!
2 · Reply
Paxhawig
Paxhawig Apr. 3 at 11:15 AM
$BTAI deadth
0 · Reply
Nickandrun
Nickandrun Apr. 2 at 3:43 PM
$BTAI I see this restabilizing somewhere around the 1.50-2.00 mark for a while, I think this area is pretty much the burns from earnings and people who decided to take major losses for no reason, underwhelming news, and repricing from firms.
1 · Reply
CADBUCK
CADBUCK Apr. 2 at 2:58 PM
$BTAI should we hold until next November or is it a dead stock ready to dilute /offfering soon?
1 · Reply
SrTxan
SrTxan Apr. 2 at 2:51 PM
$BTAI We’ve already seen the relationship between Rodman & Renshaw and HCW, the same players within the same ecosystem, where Rodman acted as the placement agent for the latest BTAI offering and holds warrants at $2.01 A few days ago they were putting out a $17 price target. HCW has had a close relationship with Rodman for over 10 years (same game, same interests) HCW hasn’t issued a real BUY on BTAI in years, yet keeps putting out high, unrealistic price targets. Anyone who says there is no conflict of interest between these firms is blatantly lying. The SEC should step in and stop allowing analysts tied to deal makers to publish completely unrealistic price targets. And it doesn’t stop there: HCW and Rodman have overlapping interests with hedge funds that are or have been involved in BTAI, many of them holding warrants at different levels. They’re trying to push us out… But at least I’m not going anywhere I’ll be here exposing all of it, and there’s a lot to expose.
2 · Reply
fatpie68
fatpie68 Apr. 2 at 2:33 PM
"Recent Street research reflects a split view on $BTAI , with some analysts emphasizing upside tied to the at-home agitation portfolio and others focusing more on the impact of equity dilution on upside potential. Some bullish analysts point to what they describe as an extreme disconnect between enterprise value and the company’s risk adjusted cash flow potential. They suggest that if core programs progress as planned, there could be room for valuation to move closer to those estimates." https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-btai/bioxcel-therapeutics/o5r3dewc-btai-upcoming-regulatory-milestones-will-drive-momentum-following-key-phase-3-success/updates/14-14-analysts-now-set-an-updated-dollar1425-price-target-for-bioxcel?utm_source=Braze&utm_medium=email&utm_campaign=CommunityDigest
0 · Reply
SrTxan
SrTxan Apr. 2 at 2:29 PM
$BTAI The fact that Selvaraju is an analyst tells you everything you need to know about HCW https://www.wallstreetzen.com/analysts/raghuram-selvaraju
0 · Reply
fatpie68
fatpie68 Apr. 2 at 2:22 PM
Another BIG DUMP for $BTAI in the first 15 minutes today. It's very cheap to borrow shares to short, and there are plenty of shares available to short, so these morning sell offs may become a trend. The Fat Cats are trying to get you to sell.
1 · Reply
SrTxan
SrTxan Apr. 2 at 2:07 PM
$BTAI Selvaraju’s track record on BTAI says it all.
0 · Reply
SrTxan
SrTxan Apr. 2 at 2:04 PM
$BTAI HCW analyst Selvaraju and his ratings… say no more…
0 · Reply
yazeed_billionare
yazeed_billionare Apr. 2 at 2:01 PM
$BTAI https://finance.yahoo.com/sectors/healthcare/articles/bioxcel-therapeutics-announces-food-drug-110000002.html Isn’t that supposed to be good news !! Why the fuck does it keep going down this stock is hillarious.
0 · Reply
Mptxop
Mptxop Apr. 2 at 1:57 PM
$BTAI who’s ready for that RS and offering? The way they burn cash is hilarious! I don’t understand why Management doesn’t pay itself living wages while in the FDA process? It’s not like they haven’t stole funds for years! Trash until September! Sell and buy back later if you are smart. Take the lose it will be worth it.
1 · Reply
SrTxan
SrTxan Apr. 2 at 1:43 PM
$BTAI HCW cutting targets again… nothing new. Same analyst, same story. Selvaraju has been wrong on BTAI over and over, yet still putting out price targets like they mean something. And let’s not forget: HC Wainwright is part of the same ecosystem as Rodman & Renshaw Who just happened to be involved in the latest offering So you have the same players Setting targets Writing reports And placing deals
0 · Reply
Boom_Badabing
Boom_Badabing Apr. 2 at 1:22 PM
$BTAI When you can't afford to sell so you just wait until FDA and market are interested in this again. I still think this is gold... Will check again in a couple of months.
0 · Reply
11thestate
11thestate Apr. 2 at 1:09 PM
$BTAI investors — don't miss your window! BioXcel Therapeutics has reached a $9.75M settlement over claims the company misled investors about its TRANQUILITY II clinical trial and FDA compliance. 📅 Claim Deadline: June 30, 2026 🗓️ Class Period: March 9, 2023 – June 28, 2023 If you bought $BTAI during that period and suffered losses, you could be entitled to a cash payout, but you need to file before the deadline to get your share. 👉 Check your eligibility and file here: https://11th.com/cases/bioxcel-investor-settlement
0 · Reply
Paxhawig
Paxhawig Apr. 2 at 11:57 AM
$BTAI true
0 · Reply
Paxhawig
Paxhawig Apr. 2 at 11:56 AM
$BTAI bullshit…. This stock is incredibel and the Management criminal
1 · Reply
DARKP00L
DARKP00L Apr. 2 at 10:43 AM
$BTAI 06:37 on Apr. 02 2026 HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5 #tradeideas
0 · Reply